. 2014 Apr 20;2014(4):CD010189. doi: 10.1002/14651858.CD010189.pub2

2. Conditioning regimen.

Study ID	Conditioning regimen intervention arm	Conditioning regimen control arm
Anasetti 2012	Myeloablative: N = 223 (80%) with cyclophosphamide (120 mg/kg) + TBI (12 Gy) N = 133 or cyclophosphamide (120 mg/kg) + busulphan (14 mg/kg orally or 11.2 mg/kg intravenously) N = 90; non‐myeloablative regimen: N = 55 (20%) with fludarabine (120 mg/m² of body‐surface area) + busulphan (250 mg/m² or 8 mg/kg) + antithymocyte globulin N = 39 or fludarabine (120 mg/m²) + melphalan (140 mg/m²) N = 16	Myeloablative: N = 208 (76%) with cyclophosphamide (120 mg/kg) + TBI (12 Gy) N = 133 or cyclophosphamide (120 mg/kg) + busulphan (14 mg/kg orally or 11.2 mg/kg intravenously N = 75; non‐myeloablative: N = 65 (24%) with fludarabine (120 mg/m² of body‐surface area) + busulphan (250 mg/m² or 8 mg/kg) + antithymocyte globulin N = 40 or fludarabine (120 mg/m²) + melphalan (140 mg/m²) N = 25
Couban 2002	Myeloablative: busulphan (1 mg/kg orally every 6 hours for 16 doses, day ‐7 to day ‐4) followed by cyclophosphamide (60 mg/kg intravenously for 2 days, day ‐3 and ‐2) N = 118 (100%)	Myeloablative: busulphan (1 mg/kg orally every 6 hours for 16 doses, day ‐7 to day ‐4) followed by cyclophosphamide (60 mg/kg intravenously for 2 days, day ‐3 and ‐2) N = 109 (100%)
Friedrichs 2010	Myeloablative: TBI (single dose or fractioned) + cyclophosphamide N = 96 (58%) or + etoposide N = 2 (1%) in standard doses or + cyclophosphamide + etoposide N = 8 (5%) or + melphalan N = 1 or + etoposide + melphalan N = 1 or busulphan + cyclophosphamide N = 54 (33%) and + etoposide N = 3 (1%) or busulphan + melphalan N = 1	Myeloablative: TBI (single dose or fractioned) + cyclophosphamide N = 101 (62%) or + etoposide N = 1 in standard doses or + cyclophosphamide + etoposide N = 3 (2%) or busulphan + cyclophosphamide N = 55 (34%), and + etoposide N = 2 (1%) or busulphan + melphalan N = 1
Heldal 2003	Myeloablative: busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) and intrathecal methotrexate (12 mg/kg) for recipients with acute myeloid leukaemia M4/5 or acute lymphoblastic leukaemia on days ‐8 and ‐4 and four times after transplantation N = 30 (100%)	Myeloablative: busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) and intrathecal methotrexate (12 mg/kg) for recipients with acute myeloid leukaemia M4/5 or acute lymphoblastic leukaemia on days ‐8 and ‐4 and four times after transplantation N = 30 (100%)
Mahmoud 1999	Only TBI (10 Gy fractioned over 4 consecutive days) + cyclophosphamide (60 mg/kg/day for 2 consecutive days) N = 15 (100%)	TBI (10 Gy fractioned over 4 consecutive days) + cyclophosphamide (60 mg/kg/day for 2 consecutive days) N = 14 (93%) or busulphan (4 mg/kg/day for 4 consecutive days) + cyclophosphamide (60 mg/kg/day for 2 consecutive days) N = 1 (7%)
Mielcarek 2011	Myeloablative: TBI (total dose 12 to 13.5 Gy) + busulphan N = 13 (14%) or + cyclophosphamide N = 30 (33%) or + etoposide N = 7 (8%) or busulphan + cyclophosphamide N = 40 (44%), busulphan + thiotepa N = 1 (1%)	Myeloablative: TBI (total dose 12 to 13.5 Gy) + busulphan N = 12 (15%) or + cyclophosphamide N = 24 (30%) or + etoposide N = 13 (16%) or + busulphan + cyclophosphamide N = 3 (4%) or busulphan + cyclophosphamide N = 29 (35%)
Mohty 2002	Myeloablative: TBI (median dose of 12 Gy and a median fraction of 6 fractions) + cyclophosphamide (120 mg/kg) N = 39 (74%) or + cyclophosphamide (120 mg/kg) + etoposide (60 mg/kg) N = 7 (13%) or + cytarabine + melphalan N = 1 (2%) or busulphan (16 mg/kg) + cyclophosphamide (200 mg/kg) N = 6 (11%)	Myeloablative: TBI (median dose of 12 Gy and a median fraction of 6 fractions) + cyclophosphamide (120 mg/kg) N = 34 (71%) or + cyclophosphamide (120 mg/kg) + etoposide (60 mg/kg) N = 4 (8%) or + cytarabine + melphalan N = 1 (2%) or busulphan (16 mg/kg) + cyclophosphamide (200 mg/kg) N = 9 (19%)
Powles 2002	Myeloablative: TBI + melphalan N = 12 (63%) or + etoposide N = 1 (5%) or busulphan + cyclophosphamide N = 6 (32%)	Myeloablative: TBI + melphalan N = 12 (60%) or + etoposide N = 1 (5%) or busulphan + cyclophosphamide N = 7 (35%)
Vigorito 2001	Myeloablative: busulphan (16 mg/kg) + cyclophosphamide (120 mg/kg) N = 16 (85%), busulphan (16 mg/kg) + cyclophosphamide (120 mg/kg) + etoposide (40 mg/kg) N = 3 (15%)	Myeloablative: TBI + cyclophosphamide (120 mg/kg) N = 1 (6%) or busulphan (16 mg/kg) + cyclophosphamide (120 mg/kg) N = 17 (94%)

TBI, total body irradiation